Evaluating Study Drug Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Recruiting
70 years - 99 years
All
Phase 2
5 participants needed
1 Location

Brief description of study

This study will test danicopan, a new drug that is being developed by Alexion to slow down progression of GA. The goals of this study are as follows: • To find out whether danicopan can slow the rate of GA disease progression, and in turn slow the loss of visual function. • To see how safe danicopan is for participants with GA by monitoring for any side effects. • To see how the body responds to treatment with danicopan. • To measure the levels of danicopan in blood over time. • To find a safe and effective dose in participants with GA and to find how the body deals with the study drug at different dose levels. • To see the effect of danicopan on health-related quality of life, on activities of daily living, and on visual functions.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Geographic Atrophy,GA,Macular Degeneration, AMD
  • Age: 70 years - 99 years
  • Gender: All

Diagnosed with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Age 70+

Updated on 04 Aug 2024. Study ID: 850569

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center